Navigation Links
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
Date:10/11/2011

LONDON, October 12, 2011 /PRNewswire/ --

- Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn's disease -

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).

"Following our successful fundraising in June, we are delighted to have now treated the first patients in the AEGIS Phase 3 programme and we remain on course to have top line results from these studies in late 2012.  Effective treatment of IDA represents a very attractive commercial opportunity and the start of recruitment is an important milestone for Shield Therapeutics as we continue the rapid development of ST10 to address this significant unmet need for the many patients with IDA." said Carl Sterritt, Chief Executive Officer and Co-Founder of Shield Therapeutics.

ST10 is an oral ferric iron-based pharmaceutical that can be administered to patients with improved tolerability compared to currently marketed oral iron treatments and also does not carry the risk of hypersensitivity reactions as is the case with currently marketed intravenous iron therapies.  Whilst prescribers often try oral ferrous products as first line therapy, many subjects prove intolerant and suffer from continuously occurring side effects, exacerbation of inflammatory lesions and failure to correct iron deficiency.  This results in the need for expensive, complicated and invasive intravenous iron therapy.  When treated with ST10, the total dose exposure of unabsorbed iron within the gastrointestinal tr
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
2. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
3. vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
6. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
7. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
8. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
9. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA and FDA ... biosimilars. , Regulatory frameworks are evolving many countries to ... complex nature of biopharmaceuticals makes the demonstration of biosimilarity ... Based on the specific aspects of biosimilar drug development ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Pathwork Diagnostics, a,genomics-based diagnostics company focused on oncology, ... has initiated an,investigational study of the Pathwork(TM) Tissue ... to help determine a tumor,s origin so that,tissue-specific ... of the first,institutions in the country to evaluate ...
... Sensor for Airborne Biological Threats Receives Government ... ... 6 ICx Technologies, a developer of,advanced technology solutions for ... its AirSentinel(R) ambient aerosol,sensors for detection of airborne biological threats. ...
... Exchange Symbol: RVX, ORLANDO, FL, Nov. ... pleased to announce today key scientific data,was ... novel features of,RVX-208, at the American Heart ... of Compound RVX-208 Increases,Serum Levels of ApoA-I ...
Cached Biology Technology:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 2Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 3Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 4ICx Awarded Department of Defense Contract for AirSentinel Monitors 2Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting 2Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting 3
(Date:7/9/2014)... concern about the prevalence of antibiotic-resistant illness, Case ... pathway to disabling disease: blocking bacteria,s access to ... how bacterial siderophore, a small molecule, captures iron ... growth as well as how the body ... Their findings appear in a recent edition of ...
(Date:7/9/2014)... global census of Adlie penguins shows that the ... percent larger than previously estimated. Adlie penguins have ... monitor and understand the effects of climate change ... using high-resolution satellite imagery, researchers from Stony Brook ... new method that permits regular monitoring of Adlie ...
(Date:7/9/2014)... laboratory testing, countless measurement results accrue. To completely ... extremely time consuming. In fact, researchers in the ... managing data, according to an online survey of ... the Fraunhofer Institute for Applied Information Technology FIT ... that they have no centralized or structured approach ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3Managing the data jungle 2Managing the data jungle 3
... Environmental and genetic factors influence a persons blood fat, ... disease (CAD). While there is some understanding of the ... defined. Now, in an international collaboration supported primarily by ... more than 25 genetic variants in 18 genes connected ...
... EVANSTON, Ill. --- Many researchers have tried to create a ... but most models have many different complicated factors, and no ... created a functional equation -- using only two parameters -- ... of Drosophila, better known as the fruit fly. They hope ...
... that facilitate the remarkably fast adaptation of intestinal bacteria ... issue of PLoS Genetics by researchers from INSERM and ... a simplified but ecologically relevant system the ... strain, Escherichia coli MG1655. E. coli is naturally resident ...
Cached Biology News:New genetic variants associated with lipid levels, risk for coronary artery disease 2New genetic variants associated with lipid levels, risk for coronary artery disease 3New genetic variants associated with lipid levels, risk for coronary artery disease 4New genetic variants associated with lipid levels, risk for coronary artery disease 5Researchers create mathematical model of fruit fly eyes 2Dissecting the genetic components of adaptation of E. coli to the mouse gut 2
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
... epitope specific for Nabeta2 is ... known proteins.,SPECIES REACTIVITIES: It ... human because the immunogen sequence ... Reactivity with other species has ...
Biology Products: